Fulvestrant Injection Global Market Report 2025

The fulvestrant injection market size has grown strongly in recent years. It will grow from $1.24 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be credited to the rising incidence of breast cancer, greater awareness of hormone receptor-positive breast cancer, the presence of branded fulvestrant products, expansion of oncology treatment infrastructure, and supportive reimbursement policies in developed nations.

The fulvestrant injection market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to a shift toward combination therapies, increased accessibility due to the introduction of biosimilars, expansion in emerging markets, a rising emphasis on personalized cancer treatment, and increased investment in clinical trials for new indications. Key trends expected during this period include advancements in fulvestrant injection, the development of combination therapies, investigation into subcutaneous delivery methods, and the integration of personalized medicine approaches through biomarker targeting.

The rising prevalence of breast cancer is anticipated to drive the growth of the fulvestrant injection market in the coming years. Breast cancer is characterized by the uncontrolled proliferation of abnormal cells in breast tissue, leading to the formation of malignant tumors that may invade nearby tissues or metastasize to other parts of the body. This increasing prevalence is largely due to aging populations, as the risk of developing breast cancer rises with age because of prolonged estrogen exposure and the gradual buildup of genetic mutations. Fulvestrant injection plays a crucial role in treating hormone receptor-positive breast cancer by blocking estrogen’s effect on tumor growth, offering an effective option for patients with advanced or treatment-resistant forms of the disease and improving overall treatment outcomes. For example, in March 2025, Breastcancer.org, a U.S.-based nonprofit organization, reported that breast cancer represents approximately 32% of all new cancer diagnoses, with an estimated 316,950 women projected to be diagnosed with invasive breast cancer and 59,080 with non-invasive types by 2025. As a result, the growing incidence of breast cancer is contributing significantly to the expansion of the fulvestrant injection market.

Leading companies in the fulvestrant injection market are prioritizing the acquisition of regulatory approvals to broaden their product portfolios and strengthen their market presence. Regulatory approvals are official authorizations granted by government agencies, confirming that a product complies with established standards for safety, efficacy, and quality. For example, in December 2022, Alembic Pharmaceuticals, an India-based pharmaceutical firm, received an Abbreviated New Drug Application (ANDA) approval from the U.S. Food & Drug Administration (USFDA) for its generic Fulvestrant injection (250 mg/5 mL), indicated for the treatment of hormone receptor-positive breast cancer. Fulvestrant is delivered via intramuscular injection, typically administered by a healthcare provider following a prescribed schedule. It functions by binding to and degrading estrogen receptors, thereby preventing estrogen from promoting the growth of hormone receptor-positive breast cancer cells.

In November 2024, Incyclix Bio LLC, a U.S.-based clinical-stage biopharmaceutical company, entered into a partnership with Eli Lilly and Company to advance the development of breast cancer treatments. The collaboration is focused on assessing whether the addition of the CDK2 inhibitor INX-315 to the existing combination of Verzenio (abemaciclib) and fulvestrant can enhance clinical outcomes in patients with HR+/HER2- metastatic breast cancer who have experienced disease progression following prior CDK4/6 inhibitor therapy. Eli Lilly and Company is a pharmaceutical company based in the United States.

Major players in the fulvestrant injection market are AstraZeneca plc, Fresenius Kabi AG, Intas Pharmaceuticals Limited, Sandoz Group AG, Apotex Inc., Dr. Reddy’s Laboratories, Cadila Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Biocon Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Alembic Pharmaceuticals, Eskayef Pharmaceuticals Ltd., Natco Pharma Ltd., Celon Laboratories Ltd., Therdose Pharma, Eugia Pharma, Formative Pharma, Halsted Pharma, and Metta Life Sciences.

North America was the largest region in the fulvestrant injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fulvestrant injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fulvestrant injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fulvestrant injection is a synthetic estrogen receptor antagonist used to treat hormone receptor-positive breast cancer in postmenopausal women. It functions by blocking and degrading estrogen receptors, thereby inhibiting the growth of cancer cells that depend on estrogen. This mechanism helps to slow or stop tumor progression, ultimately improving patient outcomes.

Fulvestrant injections are classified into original drugs and generic drugs. Original drugs refer to the first formulations developed and introduced by pharmaceutical companies. These injections come in various dosage forms, such as single-dose vials, multi-dose vials, and pre-filled syringes, and are administered via intramuscular, subcutaneous, or intravenous routes. They are used for treating breast cancer, hormone receptor-positive metastatic breast cancer, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The fulvestrant injection market research report is one of a series of new reports that provides fulvestrant injection market statistics, including fulvestrant injection industry global market size, regional shares, competitors with a fulvestrant injection market share, detailed fulvestrant injection market segments, market trends and opportunities, and any further data you may need to thrive in the fulvestrant injection industry. This fulvestrant injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fulvestrant injection market consists of sales of ready-to-use formulations and depot injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.